Physician profile
Monte H Moore
NPI 1023094901
$534.90
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $535.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $194.82 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $80.47 | 2019 | |
| Collegium Pharmaceutical, INC. | $54.40 | 2019 | |
| Stimwave Technologies Incorporated | $51.20 | 2019 | |
| Allergan, INC. | $50.19 | 2019 | |
| Saol Therapeutics INC. | $28.79 | 2019 | |
| Medtronic USA, INC. | $19.69 | 2019 | |
| Amgen INC. | $15.14 | 2019 | |
| Boston Scientific Corporation | $14.38 | 2019 | |
| Alnylam Pharmaceuticals INC. | $14.14 | 2019 | |
| Novartis Pharmaceuticals Corporation | $11.68 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monte Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.